Hormone-refractory prostate cancer

All articles from this key word are listed below.

Volume 3, Supplement 2 Supplement

New Approaches to the Treatment of Prostate Cancer

Leonard Michael Glode J Brantley Thrasher George Stark Gary J Miller Daisaku Hirano Eric Goluboff

Hormone-refractory prostate cancer Neuroendocrine cells Exisuland

Volume 5, Supplement 2 Supplement

Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer

Daniel P Petrylak

Chemotherapy Prostate-specific antigen Docetaxel Hormone-refractory prostate cancer Microtubule

Volume 5, Supplement 2 Supplement

The Role of the Urologist in Treating Patients with Hormone-Refractory Prostate Cancer

E David Crawford

Chemotherapy Hormone-refractory prostate cancer Training Urologists Reimbursement

Volume 5, Supplement 2 Supplement

A Multi-Institutional Pilot Study of Adjuvant Docetaxel for Patients with Prostate Cancer at High Risk for Relapse After Radical Prostatectomy

Mario A Eisenberger

Hormone-refractory prostate cancer Adjuvant chemotherapy Radical

Volume 5, Supplement 3 Supplement

Innovative Therapies for Prostate Cancer Treatment

Samira Syed Anthony Tolcher

Docetaxel Hormone-refractory prostate cancer Antisense oligonucleotides

Volume 5, Supplement 3 Supplement

A Multi-Institutional Pilot Study of Adjuvant Docetaxel for Patients with Prostate Cancer at High Risk for Relapse After Radical Prostatectomy

Mario A Eisenberger

Hormone-refractory prostate cancer Adjuvant chemotherapy Radical

Volume 5, Supplement 3 Supplement

Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer

Daniel P Petrylak

Chemotherapy Prostate-specific antigen Docetaxel Hormone-refractory prostate cancer Microtubule

Volume 5, Number 2 Meeting Reviews

Advances in Prostate Cancer Treatment

Highlights from the 2nd International Prostate Cancer Congress, St. Thomas, U.S. Virgin Islands

Matthew B Gretzer Alan W Partin

Prostate-specific antigen Nomograms Radiotherapy Hormone-refractory prostate cancer Radioimmunoscintigraphy Androgen blockade

Volume 9, Supplement 2 Review Articles

Treatment Options for Hormone-Refractory Prostate Cancer

Androgen-Independent Prostate Cancer

Sam S Chang

Hormone-refractory prostate cancer is a disease that includes a variety of patients and represents a treatment dilemma for the practicing physician. Because of the diversity of this group, management strategies must be targeted to the clinical situations of the individual patients and their wishes. This article outlines a logical progression of treatment choices that currently exist in this rapidly evolving field, and the landmark chemotherapy trials involving docetaxel (SWOG 9916 and TAX 327) are reviewed. Although significant progress has been made in understanding and treating hormonerefractory prostate cancer, current treatments do not yet provide a cure, and important clinical trials continue to recruit patients. [Rev Urol. 2007;9(suppl 2):S13-S18]

Chemotherapy Hormone-refractory prostate cancer Androgen-independent prostate cancer Taxanes

Volume 9, Supplement 2 Review Articles

New Paradigms for Advanced Prostate Cancer

Androgen-Independent Prostate Cancer

Daniel P Petrylak

In men with metastatic hormone-refractory prostate cancer, androgen blockade produces dramatic and rapid declines in prostate-specific antigen (PSA), bone pain, and urinary tract obstruction. Nevertheless, there have been limited options with at best palliative results for patients who progress despite a castrate testosterone level. This paradigm changed in 2004 with the publication of 2 randomized clinical trials that demonstrated a 20% to 24% survival benefit for docetaxel-based therapy when compared to mitoxantrone and prednisone, data that supported US Food and Drug Administration approval of docetaxel-based therapy for the treatment of metastatic hormone-refractory prostate cancer. This article reviews the preliminary data and the timing and sequencing implications of ongoing clinical trials. Studies are evaluating the combination of docetaxel with agents that target bone, tumor vasculature, and the vitamin D receptor as well as second-line agents, such as satraplatin. The role of immune therapy is also evolving, and further studies will define the optimal timing of chemotherapy with immune therapy. [Rev Urol. 2007;9(suppl 2):S3-S12]

Prostate cancer Docetaxel Hormone-refractory prostate cancer Androgen-independent prostate cancer

Main Content

Top Content

Highlights from the 2nd International Prostate Cancer Congress, St. Thomas, U.S. Virgin Islands

Androgen-Independent Prostate Cancer

Androgen-Independent Prostate Cancer